Abstract
Introduction: Adverse cardiovascular outcomes remain common among patients undergoing mitral transcatheter edge‐to‐edge repair (M‐TEER). Despite growing evidence supporting the cardiovascular benefits of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), large‐scale clinical data evaluating their efficacy in this specific population are limited. We aimed to assess cardiovascular outcomes associated with SGLT2i use compared with standard care using a large global research network database. Methods: A retrospective cohort study was conducted using de‐identified patient data from the TriNetX Global Research Network. Adult patients (≥ 18 years) undergoing M‐TEER were included and stratified into SGLT2i and usual care cohorts according to documented SGLT2i exposure before the index M‐TEER procedure. Propensity score matching (PSM) was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to evaluate efficacy and safety outcomes at 6 months and 1‐year follow‐up. Results: A total of 6793 patients undergoing M‐TEER were identified, of whom 2192 received SGLT2i therapy. After PSM, 1407 patients remained in each cohort. At 6 months, the primary composite outcome (stroke, all‐cause mortality, and acute heart failure) showed no significant difference between groups (HR 0.90, p = 0.508). However, significant reductions were observed in all‐cause mortality (HR 0.74, p = 0.012) and all‐cause hospitalizations (HR 0.82, p < 0.001). At 1 year, the primary composite outcome remained nonsignificant (HR 0.87, p = 0.244), while reductions in all‐cause mortality (HR 0.76, p = 0.004) and all‐cause hospitalizations (HR 0.83, p < 0.001) persisted. Conclusion: Among patients undergoing M‐TEER, baseline SGLT2i use was associated with lower all‐cause mortality and hospitalization in this observational cohort.

This publication has 36 references indexed in Scilit: